Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmsc 5.25% Regulatory News (AG99)

Share Price Information for Glaxosmsc 5.25% (AG99)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 104.575
Bid: 103.00
Ask: 106.15
Change: 0.10 (0.10%)
Spread: 3.15 (3.058%)
Open: 104.475
High: 0.00
Low: 0.00
Prev. Close: 104.475
AG99 Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EMTN Programme issue - publication of Final Terms

19 Sep 2023 15:01

RNS Number : 9623M
GlaxoSmithKline Capital PLC
19 September 2023
 

Issued: 19 September 2023, London UK

 

GlaxoSmithKline Capital plc Publication of Final Terms

 

 

The final terms dated 19 September 2023 (the "Final Terms") in respect of the issue by GlaxoSmithKline Capital plc of ¥42,500,000,000 Fixed Rate Notes due 21 September 2028 (the "Notes") is available for viewing.

 

The Notes will be guaranteed by GSK plc and will be issued under the £20,000,000,000 Euro Medium Term Note Programme (the "Programme").

 

A copy of the Final Terms has been submitted to the Financial Conduct Authority's National Storage Mechanism (NSM) submission portal via the Electronic Submission System (ESS). A copy can be viewed at:

https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

For further information, please contact:

Company SecretaryGlaxoSmithKline Capital plc980 Great West RoadBrentfordMiddlesexTW8 9GSUnited Kingdom

company.secretary@gsk.com

 

Enquiries:

 

UK Media enquiries:

Tim Foley

+44 (0) 20 8047 5502

(London)

European Analyst/Investor enquiries:

Nick Stone

James Dodwell

+44 7717 618 834

+44 7881 269 066

(London)

(London)

 

 

BASIS ON WHICH YOU MAY ACCESS THE FINAL TERMS AND THE PROSPECTUS (THE "BASE PROSPECTUS") PREPARED IN CONNECTION WITH THE PROGRAMME

Please note that the information contained in the Final Terms and the Base Prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Base Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Final Terms is not addressed. Prior to relying on the information contained in the Final Terms or the Base Prospectus you must ascertain from the Base Prospectus whether or not you are part of the intended addressees of the information contained therein.

 

Your right to access this service is conditional upon complying with the above requirements.

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com/company.

 

Registered in England & Wales:

No. 2258699

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PFTGPUBABUPWGWB
12
Date   Source Headline
4th Aug 20152:34 pmRNSPublication of Prospectus
29th Jul 20155:41 pmRNSHalf Yearly Report
30th Apr 201512:08 pmRNSAnnual Financial Report
28th Nov 20145:00 pmRNSPublication of Final Terms
28th Nov 20145:00 pmRNSPublication of Final Terms
27th Oct 20146:34 pmRNSPublication of Supplementary Prospectus
27th Oct 20146:30 pmRNSPublication of Supplementary Prospectus
4th Aug 20141:25 pmRNSPublication of Prospectus
31st Jul 20143:45 pmRNSHalf Yearly Report
28th Apr 20145:43 pmRNSAnnual Financial Report
5th Aug 201312:35 pmRNSPublication of Prospectus
30th Jul 20132:32 pmRNSHalf Yearly Report
16th Apr 201312:45 pmRNSAnnual Financial Report
17th Dec 20129:56 amRNSIssue of Debt
7th Dec 20127:00 amRNSPublication of Prospectus
5th Sep 20122:26 pmRNSPublication of Prospectus
5th Sep 20122:25 pmRNSPublication of Prospectus
1st Aug 20125:13 pmRNSHalf Yearly Report
30th Apr 20123:57 pmRNSAnnual Information Update
24th Apr 20124:46 pmRNSAnnual Financial Report
3rd Aug 20112:18 pmRNSPublication of Prospectus
3rd Aug 20112:17 pmRNSPublication of Registration Document
2nd Aug 20116:09 pmRNSHalf Yearly Report
28th Apr 20112:30 pmRNSAnnual Information Update
27th Apr 20114:50 pmRNSAnnual Financial Report
7th Jan 20114:12 pmRNSDirector/PDMR Shareholding
19th Aug 20105:20 pmRNSHalf Yearly Report
30th Apr 20106:05 pmRNSAnnual Information Update
30th Apr 20104:07 pmRNSAnnual Financial Report
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.